Comprehensive Contract Research Organization (CRO)

Mid-Atlantic U.S.
Business Services; Healthcare
Client Code: BN000041203
Revenue (Internal): $15,436,552
EBITDA (Internal): $7,582,955

Comprehensive contract research organization with specialization in clinical testing, product and assay development in the pharmaceutical and biotechnology space.

Key Aspects

• The firm's revenue has grown at a compound annual growth rate of 67.6% (CAGR) over the last four years

• Comprehensive contract research organization and high complexity CLIA (Clinical Laboratory Improvement Amendments) certified laboratory

• Specialist in next generation sequencing technologies in both a clinical and research setting

• The firm develops and validates custom clinical assays specialized for the scope and context of the research assignment

• Multiple high-profile clinical assays and development partnerships for cutting edge products


• The company is actively expanding its portfolio of clinical tests and assays, several of which will reach the market in the next twelve months

• Capitalize on the ongoing need for covid-19 testing and analysis, the firm has been an early leader in this space and has all necessary relationships and infrastructure to operate in perpetuity

• Combine synergies of other CROs to create a broader addressable marketplace for cutting edge research, development, and clinical testing 


• Mid-Atlantic U.S.

Current Markets

• The company is licensed in all 50 states to perform clinical and non-clinical research and testing in the biotechnology and pharmaceutical space. The company services many different institutions including: government agencies, large commercial pharmaceutical companies, academic institutions